Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels

HIGHLIGHTS

• who: Haneesha Mohan from the Toronto General Hospital Research Institute, Princess Margaret Cancer Research Tower (PMCRT), University Health Network, College Street, th Floor, Room, Toronto, Ontario M G , Canada have published the article: Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels, in the Journal: (JOURNAL) of 25/Nov/2020
• what: Funding: This project has been funded with Federal funds from the Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Department of Health and Human Services under Contract . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.